Yahoo Poland Wyszukiwanie w Internecie

Search results

1. pmc.ncbi.nlm.nih.gov › articles › PMC9063254Efficacy of GLP-1 RA Approved for Weight Management in Patients...

   pmc.ncbi.nlm.nih.gov › articles › PMC9063254

   The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity. The reliable models that might predict weight reducing potential at the individual level have not been identified yet.

   • GLP−1 receptor agonists for the treatment of obesity: Role as a ...

     SMG is an analog of long-acting GLP-1, mainly used to...

   • GLP-1RAs for the treatment of obesity in women after menopause

     GLP-1RAs for the treatment of obesity in women after...

2. pmc.ncbi.nlm.nih.gov › articles › PMC9945324GLP−1 receptor agonists for the treatment of obesity: Role as a...

   pmc.ncbi.nlm.nih.gov › articles › PMC9945324

   SMG is an analog of long-acting GLP-1, mainly used to control T2DM, and is also suitable for promoting weight loss in people with mild obesity (95, 96). The usage for treating obesity is subcutaneous injection once a week. For both diabetic and non-diabetic patients, the drug can reduce weight (97, 98).

3. www.maturitas.org › article › S0378-5122(21)00347-9GLP-1RAs for the treatment of obesity in women after menopause

   www.maturitas.org › article › S0378-5122(21)00347-9

   Current guidelines for the treatment of obesity in adults suggest escalation of therapeutic measures according to BMI and the presence of comorbidities.

4. www.thelancet.com › journals › eclinmGLP-1 receptor agonists for weight reduction in people living...

   www.thelancet.com › journals › eclinm

   Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially approved for improvement of metabolic control in patients living with diabetes. 1 However, recent randomised controlled trials (RCTs) have demonstrated the efficacy of some GLP-1 RAs for weight reduction in adults even without diabetes, leading to semaglutide and liraglutide ...

5. pubmed.ncbi.nlm.nih.gov › 34922787GLP-1RAs for the treatment of obesity in women after menopause

   pubmed.ncbi.nlm.nih.gov › 34922787

   GLP-1RAs for the treatment of obesity in women after menopause. Maturitas. 2022 Feb:156:65-66. doi: 10.1016/j.maturitas.2021.12.003. Epub 2021 Dec 11. Authors. Stavroula A Paschou 1 , Kalliopi Kotsa 2 , Melpomeni Peppa 3 , Erifili Hatziagelaki 3 , Theodora Psaltopoulou 4. Affiliations.

6. journals.viamedica.pl › endokrynologia_polska › articleTherapy of obesity in women with PCOS using GLP-1 analogues —...

   journals.viamedica.pl › endokrynologia_polska › article

   • Zapisane w pamięci cache

   24 kwi 2022 · Dane oparte na dowodach jednoznacznie potwierdziły zasadność stosowania analogów peptydu glukagonopodobnego 1 (GLP-1) w leczeniu pacjentek z nadwagą/otyłością i PCOS. Efektem terapii GLP-1 jest nie tylko redukcja masy ciała, ale także poprawa wskaźników insulinooporności oraz zmniejszenie hiperandrogenemii.

7. www.sciencedirect.com › science › articleEffects of GLP-1 agonists on proportion of weight loss in obesity...

   www.sciencedirect.com › science › article

   1 paź 2022 · Objective. To determine effects of glucagon-like peptide-1 (GLP-1) receptor agonists on ≥5% or ≥10% weight loss in overweight or obese patients with or without type 2 diabetes mellitus (T2DM). Methods. A systematic review and meta-analysis of placebo-controlled, randomized clinical trials (RCTs) ≥12 weeks’ duration.